Clinical Trial Update: Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial is evaluating durvalumab and tremelimumab with chemoradiation before surgery for esophageal and gastroesophageal junction adenocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• IMFINZI (DURVALUMAB)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING